IL309422A - Antibodies against CSP - Google Patents

Antibodies against CSP

Info

Publication number
IL309422A
IL309422A IL309422A IL30942223A IL309422A IL 309422 A IL309422 A IL 309422A IL 309422 A IL309422 A IL 309422A IL 30942223 A IL30942223 A IL 30942223A IL 309422 A IL309422 A IL 309422A
Authority
IL
Israel
Prior art keywords
seq
amino acid
set forth
acid sequence
sequence set
Prior art date
Application number
IL309422A
Other languages
English (en)
Hebrew (he)
Inventor
Daniel Eric Emerling
Randal R Ketchem
Shaun M Lippow
Wayne Volkmuth
Katherine L Williams
Original Assignee
Atreca Inc
Daniel Eric Emerling
Randal R Ketchem
Shaun M Lippow
Wayne Volkmuth
Katherine L Williams
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atreca Inc, Daniel Eric Emerling, Randal R Ketchem, Shaun M Lippow, Wayne Volkmuth, Katherine L Williams filed Critical Atreca Inc
Publication of IL309422A publication Critical patent/IL309422A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL309422A 2021-06-17 2022-06-16 Antibodies against CSP IL309422A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163211820P 2021-06-17 2021-06-17
PCT/US2022/033877 WO2022266383A1 (en) 2021-06-17 2022-06-16 Anti-csp antibodies

Publications (1)

Publication Number Publication Date
IL309422A true IL309422A (en) 2024-02-01

Family

ID=84526612

Family Applications (1)

Application Number Title Priority Date Filing Date
IL309422A IL309422A (en) 2021-06-17 2022-06-16 Antibodies against CSP

Country Status (9)

Country Link
US (2) US11655290B2 (cg-RX-API-DMAC7.html)
EP (1) EP4355774A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024524895A (cg-RX-API-DMAC7.html)
KR (1) KR20240047964A (cg-RX-API-DMAC7.html)
CN (1) CN117940450A (cg-RX-API-DMAC7.html)
AU (2) AU2022292722B2 (cg-RX-API-DMAC7.html)
IL (1) IL309422A (cg-RX-API-DMAC7.html)
MX (1) MX2023014984A (cg-RX-API-DMAC7.html)
WO (1) WO2022266383A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322413A (en) * 2023-02-03 2025-09-01 Atreca Inc Variants of anti-CSP antibody
WO2025194069A1 (en) * 2024-03-15 2025-09-18 Atreca, Inc. Anti-csp antibody variants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3954643B2 (ja) 1991-11-16 2007-08-08 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム マラリア原虫由来のCSおよびHBsAG間のハイブリッド蛋白質
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US9221902B2 (en) * 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
SG10201900183VA (en) * 2011-04-28 2019-05-30 Univ Leland Stanford Junior Identification of polynucleotides associated with a sample
KR20180029253A (ko) * 2015-07-22 2018-03-20 유레카 쎄라퓨틱스, 인코포레이티드 Psa 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도
US11066464B2 (en) * 2016-03-21 2021-07-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
US20220195023A1 (en) 2019-02-19 2022-06-23 Atreca, Inc. Anti-csp antibody variants

Also Published As

Publication number Publication date
AU2022292722A1 (en) 2024-01-04
KR20240047964A (ko) 2024-04-12
US11655290B2 (en) 2023-05-23
MX2023014984A (es) 2024-03-12
EP4355774A4 (en) 2025-05-07
WO2022266383A1 (en) 2022-12-22
US12545723B2 (en) 2026-02-10
AU2022292722B2 (en) 2025-05-22
AU2025220692A1 (en) 2025-09-11
CN117940450A (zh) 2024-04-26
JP2024524895A (ja) 2024-07-09
NZ806561A (en) 2025-06-27
US20230167169A1 (en) 2023-06-01
EP4355774A1 (en) 2024-04-24
US20230002483A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
US20260115254A1 (en) Immune-cell targeted bispecific chimeric proteins and uses thereof
CN110914306B (zh) 检查点抑制物双特异性抗体
KR102597804B1 (ko) 이중 특이적 항체
IL312961A (en) Anti-tmprss2 antibodies and antigen-binding fragments
JP2022116269A5 (cg-RX-API-DMAC7.html)
WO2007108559A8 (ja) ヒトトロンボポエチン受容体に対するアゴニスト抗体
JP2017507954A5 (cg-RX-API-DMAC7.html)
IL321095A (en) Anti-c-met antibody drug conjugates
JP2021533204A5 (cg-RX-API-DMAC7.html)
CA2901468C (en) Pan-elr+ cxc chemokine antibodies
KR20080068105A (ko) 뉴로필린 길항제
EP2718323A2 (en) Human antigen binding proteins that bind to a complex comprising beta-klotho and an fgf receptor
RU2013143358A (ru) Анти-fgfr4 антитела и способы их применения
RU2013155906A (ru) Антитела анти-angptl3 и их применение
FI3773738T3 (fi) Vasta-aine-lääkekonjugaatteja ja niiden käyttöjä syövän hoitamiseksi
JP2024527607A5 (cg-RX-API-DMAC7.html)
JP2022528005A5 (cg-RX-API-DMAC7.html)
JP2021510523A5 (cg-RX-API-DMAC7.html)
RU2004124847A (ru) Агонисты рецептора кортикотропин-рилизинг фактора 2
JP2025503704A5 (cg-RX-API-DMAC7.html)
JP2024524895A5 (cg-RX-API-DMAC7.html)
JP2021533142A5 (cg-RX-API-DMAC7.html)
WO2024192235A3 (en) Nanobody-based protein degraders and related methods
JP2025509555A5 (cg-RX-API-DMAC7.html)
CN112996540A (zh) 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途